Wegovy Pill Shows Promising Weight Loss Results in Trials
TL;DR Summary
A clinical trial shows that an oral form of Wegovy is as effective as the injectable version in promoting weight loss, with patients losing around 16.6% of their body weight over 64 weeks, fueling optimism for expanding weight-loss treatments. Both Novo Nordisk and Eli Lilly are racing to bring their oral obesity drugs to market, with promising trial results and plans for FDA approval, despite side effects and adherence challenges.
- Wegovy pill could deliver as much weight loss as the shot, trial shows The Washington Post
- GLP-1 Wegovy Pill Leads To 13% Weight Loss In Semaglutide Trial TODAY.com
- Novo Nordisk shares climb after positive anti-obesity pill results The Guardian
- Novo Nordisk pads case for Wegovy in a pill as oral obesity asset nears FDA decision Fierce Pharma
- Novo Nordisk shares pop 5% after Wegovy pill trial shows 'significant' weight reduction CNBC
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
90%
682 → 70 words
Want the full story? Read the original article
Read on The Washington Post